|
The
mystic report
Mashelkar report could be the biggest controversy of the pharma
industry. Following the storm that the report has created,
it was withdrawn and Mashelkar has resigned from the group
but the verdict is yet to come. Sushmi Dey finds out what
went wrong
Upfront
Orchid
forays in the Canadian generic market
Orchid Chemicals and Pharmaceuticals received a formal approval
from the Canadian TPD (Therapeutic Product Directorate) for
two of its ANDS (Abbreviated New Drug Submissions) applications.
Roche
launches Neulastim
Roche has announced the availability of the drug Neulastim
(pegfilgrastim) in India.
Lupin
receives US FDA Approval for Suprax
The USFDA has approved Lupin's application for Suprax Cefixime
for oral suspension 200mg/5ml.
Novamed
to secure Veeda
Novamed a pharmaceutical company headquartered in Shanghai,
China, as a part of its commercial model is planning to facilitate
clinical development work in China, India and South Africa
on behalf of international companies that are not present
or focused in these geographies.
ICRI
awarded UKIERI grant
Institute of Clinical Research (India), ICRI was awarded the
prestigious UK India Education and Research Initiative (UKIERI)
award, an initiative of United Kingdom and India for working
together in education and for initiating higher education
programme in India for Translational Medicine and Molecular
Biology.
Alembic
hits on chronic segment
Alembic has completed the acquisition of the entire non-oncology
formulation business of Dabur Pharma. It will have the full
rights to market the 24 brands as part of this acquisition.
Glenmark
and Dyax join hands
Glenmark Pharmaceuticals SA (the wholly owned Swiss subsidiary
of Glenmark Pharmaceuticals) and Dyax, entered into a funded
research agreement for the discovery of therapeutic antibodies.
Synchron
to acquire Innovance
Synchron Research Services has announced the acquisition of
Innovance, a start up contract research organisation based
in Ahmedabad. The deal was facilitated by Deloitte.
Products
Upcoming
Events
'Indian
pharma has renewed vigour'
Holly Haughney, Pall India's Vice-President, Biopharmaceuticals,
Marketing-Asia speaks to Nandini Patwardhan about the company,
its focus on the biopharma market and its foray into the country.
Enzymes-Small
substances, big benefits
Enzymes are the catalysts of chemical reaction in the human
body. Advanced Enzyme Technologies sheds light on enzymes
and their benefits for the human body.
|
